Influence of Sarcopenia on the Course of the Diseases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversitatsmedizin Mainz - 1. Medizinische Klinik
About this trial
Frailty is a geriatric syndrome that primarily affects older patients, but also patients with severe illnesses. It is particularly common among oncology patients, but also among patients with gastrointestinal diseases such as liver cirrhosis or pancreatitis. Sarcopenia, a form of frailty, is defined as a loss of muscle quantity, quality and function. Currently, complex methods such as CT or bioimpedance measurement are available. However, simpler techniques such as ultrasound-based measurement could be alternatives, but still require further validation. In addition, serological muscle markers could support and simplify diagnostics.
The aim of this project is to be able to estimate the prognosis of patients at an early stage by measuring sarcopenia using ultrasound and biomarkers.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
oncological patient in the field of gastrointestinal tumors
patients with liver cirrhosis
patients attending the intensive care unit
Disqualifiers
patients incapable of consenting
patients with congenital muscle diseases
Trial population
oncological patient in the field of gastrointestinal tumors patients with liver cirrhosis patients attending the intensive care unit
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Ultrasound
Diagnostic testSonographisch measurement of muscles Blood muscle markers
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Complication
Number of patients with decompensation of the underlying disease (e.g. liver cirrhosis: hyropic decompensation) or hospitalisation or death
Time frame
From the date of enrollment until the date of first documented complication (decopmensation, hospitalisation, death) from any cause whichever came first, assessed up to two yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov